Gao Yuanjin, Zheng Lili, Liang Ping, Cheng Zhigang, Han Zhiyu, Tan Shui-Lian, Yu Xiaoling
Department of Interventional Ultrasound, State Key Laboratory of Kidney Disease, The Chinese PLA General Hospital, Beijing 100853, China.
J Cancer Res Ther. 2020 Sep;16(5):1088-1092. doi: 10.4103/jcrt.JCRT_1119_19.
Microwave ablation (MWA) has been proven as a promising method to treat solid tumors.
This study aims to evaluate the efficacy and safety of ultrasound (US)-guided MWA for treating adrenal metastasis and to explore the factors affecting survival.
This was a retrospective study performed on patients treated at our department.
A total of 43 patients with adrenal metastasis (22 hepatocellular carcinoma, eight renal cell carcinoma, five non-small cell lung cancer, four colorectal cancer, three liposarcoma, and one malignant fibrous histiocytoma) were enrolled. All patients were treated at our department at least once. The treatment protocol for each patient, the technique used, and the survival details were recorded.
Statistical analyses were performed using SPSS 26.0 software.
Technical success was achieved in all cases. MWA was a safe technique for treating all types of metastasis. No major complications were observed. The pathology of adrenal lesions was the significant risk factor contributing to overall survival (OS) (P = 0.040). The 1-year and 3-year OS rates for all patients were 0.828 and 0.389, respectively.
Percutaneous US-guided MWA is safe and effective in terms of local control and survival of adrenal metastasis.
微波消融（MWA）已被证明是一种治疗实体瘤的有前景的方法。
本研究旨在评估超声（US）引导下MWA治疗肾上腺转移瘤的疗效和安全性，并探讨影响生存的因素。
这是一项对在我科接受治疗的患者进行的回顾性研究。
共纳入43例肾上腺转移瘤患者（22例肝细胞癌、8例肾细胞癌、5例非小细胞肺癌、4例结直肠癌、3例脂肪肉瘤和1例恶性纤维组织细胞瘤）。所有患者均在我科至少接受过一次治疗。记录每位患者的治疗方案、使用的技术及生存细节。
使用SPSS 26.0软件进行统计分析。
所有病例均取得技术成功。MWA是治疗所有类型转移瘤的安全技术。未观察到严重并发症。肾上腺病变的病理类型是影响总生存期（OS）的显著危险因素（P = 0.040）。所有患者的1年和3年OS率分别为0.828和0.389。
经皮US引导下MWA在肾上腺转移瘤的局部控制和生存方面是安全有效的。
